Cytokinetics may walk a lonely road to market with tarnished heart med omecamtiv after last partner bows out
Once flush with partners for heart failure drug omecamtiv mecarbil, Cytokinetics watched its longtime ally Amgen flee last month over weak data from a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
